Mounjaro vs Ozempic for Type 2 Diabetes: Which Is Better?

Research-informed explainer — last updated 2026-04-11

Tirzepatide (Mounjaro) produces greater A1c reduction and greater weight loss than semaglutide (Ozempic) in the best available trial data — but both drugs are excellent options for type 2 diabetes, and the right choice depends on your cardiovascular history, side effect tolerance, insurance coverage, and weight loss goals. No head-to-head cardiovascular outcomes trial for tirzepatide has been completed yet, which matters for patients with established heart disease.

This explainer draws on clinical trial data and the ADA/EASD 2022 treatment consensus, with contributions from three endocrinologists in the Convene directory whose published work includes SURMOUNT-2, STEP-2, SUSTAIN-7, and SUSTAIN-6.

How each drug works: GLP-1 vs dual GIP/GLP-1

Both Ozempic and Mounjaro lower blood sugar and promote weight loss, but their mechanisms differ in an important way.

Semaglutide (Ozempic) is a GLP-1 receptor agonist. GLP-1 is a hormone released by the gut after eating. It tells the pancreas to release insulin when blood sugar rises, suppresses glucagon (which would otherwise raise blood sugar), slows gastric emptying so food moves through the stomach more gradually, and signals the brain to reduce appetite. Semaglutide mimics this hormone with a longer half-life, making once-weekly injection practical.

Tirzepatide (Mounjaro) is a dual GIP/GLP-1 receptor agonist — the first of its class approved for type 2 diabetes. It activates both GLP-1 receptors and GIP (glucose-dependent insulinotropic polypeptide) receptors simultaneously. GIP is another gut hormone that amplifies insulin secretion and, in the context of GLP-1 activation, appears to enhance weight loss beyond what GLP-1 agonism alone can achieve. The exact mechanism by which GIP addition amplifies metabolic effects is still being characterized, but the clinical data make the outcome clear: the dual mechanism produces larger reductions in both A1c and body weight than GLP-1 alone.

At a glance

A1c reduction: what the trials show

For most people with type 2 diabetes, the primary goal is lowering hemoglobin A1c — the three-month average blood sugar measure that predicts long-term complications.

The SURPASS trial program, which established tirzepatide for T2D, showed A1c reductions ranging from approximately −1.9% to −2.6% at the 15 mg dose, depending on the trial population. In SURPASS-2, the head-to-head comparing tirzepatide to semaglutide 1 mg (the standard Ozempic dose for T2D), tirzepatide at all three doses produced statistically significantly greater A1c reduction.

Semaglutide's performance is well-established. In the STEP-2 trial, which tested the higher 2.4 mg dose specifically in patients with type 2 diabetes, A1c fell by approximately −1.6% from baseline [4]. At the standard 1 mg Ozempic dose, reductions in the SUSTAIN program were in the −1.4% to −1.8% range. SUSTAIN-7 showed that semaglutide 1 mg outperformed dulaglutide 1.5 mg on both A1c and weight, establishing semaglutide's place at the top of the GLP-1 class before tirzepatide arrived [5].

For patients who need to reach a specific A1c target and have not reached it on existing therapy, tirzepatide offers a modest but real advantage in blood sugar control.

Weight loss: where the difference becomes substantial

The weight loss gap between the two drugs is larger than the A1c gap, and for many patients with type 2 diabetes and obesity, it is the deciding factor.

SURMOUNT-2, the phase 3 trial of tirzepatide in people with type 2 diabetes and obesity, reported mean body weight reductions of −13.9% at 10 mg and −15.7% at 15 mg, compared to −3.3% in the placebo group [2]. Those are the largest weight losses ever recorded in a phase 3 trial in this population. For a 250-pound person, a 15% reduction means losing approximately 37 pounds.

In STEP-2, semaglutide 2.4 mg (the higher dose, sold as Wegovy for obesity rather than the standard Ozempic dose) produced −9.6% body weight reduction in T2D patients [4]. That is a meaningful result, but tirzepatide's 15 mg dose outperforms it by roughly 6 percentage points in the same population type.

One important context: SURMOUNT-2 and STEP-2 used different doses. The SURMOUNT-2 tirzepatide doses of 10 mg and 15 mg are higher than the starting dose of 5 mg. The comparison is not perfectly symmetrical, but it reflects real-world prescribing patterns — both drugs are titrated upward as tolerated.

For patients whose primary concern is weight management alongside diabetes control, the data consistently favors tirzepatide.

Cardiovascular outcomes: where semaglutide has a clear advantage

This is the most clinically significant difference between the two drugs for patients with established cardiovascular disease.

SUSTAIN-6, a large cardiovascular outcomes trial (CVOT), enrolled over 3,000 patients with type 2 diabetes at high cardiovascular risk and randomized them to semaglutide or placebo on top of standard care. Semaglutide reduced the composite of cardiovascular death, nonfatal myocardial infarction, and nonfatal stroke (MACE) by 26% compared to placebo [3]. That trial also established semaglutide's safety profile in patients with prior heart attacks, strokes, and heart failure.

Tirzepatide has no completed cardiovascular outcomes trial as of April 2026. SURPASS-CVOT is ongoing but results have not been reported. There are favorable surrogate markers — blood pressure reductions, lipid improvements, and weight loss itself reduces cardiovascular risk — but surrogate markers are not the same as outcomes data. For a patient with a recent heart attack or heart failure, an endocrinologist who prioritizes proven cardiovascular event reduction will typically choose semaglutide until SURPASS-CVOT reports.

The ADA/EASD 2022 consensus statement, which was updated to include tirzepatide after the SURPASS trials, reflects this nuance: both agents are recommended, but the framework gives priority to agents with established cardiovascular benefit for patients in the highest-risk cardiovascular category [6].

Side effects: similar profiles, possible nausea differences

Both drugs share a GLP-1-related side effect profile. The most common complaints are nausea, vomiting, diarrhea, and constipation. These are most pronounced when starting the drug or moving to a higher dose, and they diminish for most patients over time. Both are given by once-weekly subcutaneous injection.

The key mitigation strategy is the same for both: slow titration. Starting at the lowest dose and increasing only every four to eight weeks, with food choices that avoid large meals and high-fat foods, reduces GI side effects substantially.

There is some suggestion from clinical trial adverse event reporting that tirzepatide may carry a modestly lower rate of nausea than semaglutide, possibly because the GIP component tempers the GI effects of GLP-1 activation. The data are not definitive enough to treat this as a clinical decision point, but it is worth discussing with your endocrinologist if nausea on semaglutide has been a barrier to dose escalation.

Both drugs are contraindicated in patients with a personal or family history of medullary thyroid carcinoma or multiple endocrine neoplasia syndrome type 2, based on rodent carcinogenicity data (though causality in humans has not been established). Pancreatitis has been reported with GLP-1 receptor agonists as a class; the risk is low but relevant for patients with a history of pancreatitis.

Cost and insurance coverage

Both drugs carry list prices around $900–$1,100 per month without insurance. The out-of-pocket cost with insurance depends on your plan's formulary, tier placement, and whether a prior authorization is required.

For type 2 diabetes, both drugs are generally covered by commercial insurance and Medicare Part D, though coverage tiers and step-therapy requirements vary widely. Manufacturer copay cards (Lilly for Mounjaro, Novo Nordisk for Ozempic) can reduce out-of-pocket costs substantially for commercially insured patients, but these cards cannot be used with Medicare or Medicaid.

The practical reality: insurance formulary placement often determines the initial choice between these drugs more than the clinical data does. If your plan covers one but not the other without prior authorization, that is worth factoring in before starting a conversation about which is clinically superior.

Who each drug is better suited for

These are general patterns, not rules. Your endocrinologist will integrate your full clinical picture.

Tirzepatide tends to be a better fit when:

• Weight loss is a primary goal alongside blood sugar control
• Prior GLP-1 agonist therapy has not achieved adequate A1c reduction
• You do not have established cardiovascular disease requiring proven MACE reduction
• Your insurance covers it on a favorable tier

Semaglutide tends to be a better fit when:

• You have established cardiovascular disease (prior heart attack, stroke, or symptomatic atherosclerosis) and your endocrinologist wants proven MACE reduction
• You have had adequate response to GLP-1 class agents previously
• Insurance coverage or cost strongly favors it
• You are switching from another GLP-1 agonist and prefer continuity within the class

The 2022 ADA/EASD consensus positions both drugs in the same tier for most patients with type 2 diabetes and high cardiovascular risk, but notes the importance of individualized treatment decisions. For patients with obesity as a primary driver of disease burden, the newer trial data increasingly points toward tirzepatide.

Questions to ask your endocrinologist

• Based on my A1c target and weight loss goals, do you recommend tirzepatide or semaglutide as the better starting point?
• Do I have cardiovascular disease or risk factors that make the SUSTAIN-6 outcomes data relevant to my choice?
• Which drug does my insurance cover, and what is the expected out-of-pocket cost for each?
• How should I manage nausea during the titration period, and what is the dose escalation schedule?
• If I do not tolerate one drug, is the other a reasonable switch?
• How long should I expect to be on this medication, and what happens if I stop taking it?

The bottom line

Tirzepatide (Mounjaro) produces greater A1c reduction and meaningfully greater weight loss than semaglutide (Ozempic) in clinical trial data — this is not a close call in the metabolic efficacy comparison. For patients who prioritize weight loss or have not reached A1c targets on existing GLP-1 therapy, the evidence favors tirzepatide.

But semaglutide holds one advantage that tirzepatide currently cannot match: eight years of cardiovascular outcomes data, including SUSTAIN-6's 26% MACE reduction in high-risk patients. Until SURPASS-CVOT reports, patients with established heart disease have a stronger evidence base with semaglutide.

For most people with type 2 diabetes who do not have established cardiovascular disease, tirzepatide is the more powerful metabolic tool. For the highest-risk cardiovascular patients, your endocrinologist will weigh the absence of CVOT data carefully. In both cases, the decision belongs in a conversation with a specialist who knows your full history — not in a comparison article.